Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Argan Inc’s contract backlog or spotting cost-overrun warnings means sifting through hundreds of EPC disclosures. Each 10-K details percentage-of-completion accounting, while every 8-K can signal a newly awarded gas-fired or renewable project. The problem? These filings are dense and highly technical.
Stock Titan’s AI-powered summaries turn that challenge into a two-minute read. We monitor EDGAR around the clock, surface key data as soon as a document posts, and translate accounting jargon into plain language. Whether you need the latest Argan Inc quarterly earnings report 10-Q filing to gauge segment margins or want real-time alerts on Form 4 insider moves, you’ll find it here—already distilled and cross-referenced.
- Argan Inc insider trading Form 4 transactions—track executive buys and sells within minutes.
- Argan Inc quarterly earnings report 10-Q filing—see segment revenue and backlog updates.
- Argan Inc Form 4 insider transactions real-time—receive instant alerts on material moves.
- Argan Inc SEC filings explained simply—our AI distills complex EPC disclosures.
- Argan Inc earnings report filing analysis—compare contract margins quarter over quarter.
- understanding Argan Inc SEC documents with AI—skip jargon, keep the insight.
- Argan Inc executive stock transactions Form 4—evaluate alignment of management incentives.
- Argan Inc annual report 10-K simplified—find risk factors on fixed-price contracts fast.
- Argan Inc proxy statement executive compensation—review pay tied to project milestones.
- Argan Inc 8-K material events explained—know when new EPC awards hit the books.
You can also download original PDFs, compare historical 10-Qs, and export tables for modeling—without leaving this page. From backlog disclosures to cash-flow swings, our expert analysis highlights what moves the stock so you can make informed decisions sooner.
Richard H. Deily, a former CFO and current officer of Argan, Inc. (AGX), reported transactions on 09/12/2025. The filing shows a sale of 7,802 shares of common stock. After the reported sale, the Form 4 lists the reporting persons remaining direct holdings in common stock attributable to outstanding equity awards: 10,000 shares underlying a 04/12/2020 option, 3,500 from a 04/16/2022 option, 2,500 from a 04/17/2024 option, 4,166 time-based RSUs scheduled to vest on 09/13/2025, and 7,500 of various performance-based RSUs/targets. The filing includes detailed vesting and payout conditions for the PRSUs and EPSRSUs with potential payouts from 0% to 200% depending on performance.
Argan, Inc. reports three reportable business segments and had 15,828,289 shares issued with 13,811,575 shares outstanding at July 31, 2025. The company is evaluating adoption of ASU 2023-09 on income tax disclosures. Approximately 26% of the remaining unrecognized performance obligations at July 31, 2025 are expected to be recognized in fiscal 2026, with the remainder in fiscal 2027–2029. The company has a revolving credit facility of $35.0 million priced at SOFR+1.85% with a $30.0 million accordion and a $25.0 million companion facility for letters of credit. Bonds covering warranty and retention obligations totaled $61.2 million. A $9.7 million letter of credit draw is disputed and included in accounts receivable. The IRS has disallowed R&D credits for fiscal 2021–2022; the company is contesting that finding and filed an insurance claim. Argan repurchased 56,117 shares for approximately $7.0 million during the six months ended July 31, 2025. Significant customer concentration remains in Power Industry Services, with top customers representing notable portions of revenue.
Charles E. Collins IV, Chief Executive Officer of Argan, Inc. (AGX), reported amended insider transactions on Form 4/A. On 07/29/2025 he exercised 1,500 stock options at $46.35 and sold the same 1,500 shares on the open market at an average price of $241.50, leaving him with 22,506 shares. On 07/31/2025 he exercised 2,735 options at $46.35 and 2,265 options at $43.10, then sold 5,000 shares on the open market at an average price of $245, resulting in 21,006 shares beneficially owned following the reported transactions. The filings list option exercise dates and original grant dates and show the exercises were from options granted 01/11/2019 and 09/12/2019. The Form is signed by Mr. Collins on 08/29/2025.
Argan, Inc. (AGX) – Form 144 insider sale notice
Insider John R. Jeffrey, Jr. has filed to sell up to 2,621 common shares through Charles Schwab on or about 29 Jul 2025. The proposed sale equals roughly 0.02 % of the 13.64 m shares outstanding and carries an aggregate market value of $623,798, implying a per-share price near $238.
The shares derive from two recent equity grants: a time-based restricted stock issuance of 390 shares on 13 Jun 2025 and an option-exercise grant of 7,731 shares on 17 Jan 2025. Over the past three months the same insider sold 5,500 shares on 9 Jun 2025 for gross proceeds of $1.20 m. The filer certifies awareness of no undisclosed adverse information and affirms compliance with Rule 144. No operational, earnings or guidance data are included in this filing.
FAQ
What is the current stock price of Argan (AGX)?
What is the market cap of Argan (AGX)?
